Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by Wedbush to “Strong-Buy” Rating

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by stock analysts at Wedbush to a “strong-buy” rating in a report issued on Monday, Zacks.com reports.

Other equities research analysts have also issued research reports about the stock. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, September 5th. Evercore ISI raised their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. Bank of America increased their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Citigroup lifted their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Finally, The Goldman Sachs Group raised their price target on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $195.92.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock opened at $128.13 on Monday. Ascendis Pharma A/S has a 1-year low of $86.54 and a 1-year high of $161.00. The stock has a market capitalization of $7.77 billion, a price-to-earnings ratio of -13.76 and a beta of 0.66. The business has a fifty day moving average price of $133.17 and a 200-day moving average price of $133.46.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. On average, equities research analysts anticipate that Ascendis Pharma A/S will post -7.24 earnings per share for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. lifted its stake in Ascendis Pharma A/S by 10.0% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 7,622 shares of the biotechnology company’s stock worth $1,138,000 after acquiring an additional 695 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new position in shares of Ascendis Pharma A/S in the third quarter valued at approximately $1,212,000. Assetmark Inc. purchased a new stake in Ascendis Pharma A/S during the 3rd quarter worth approximately $331,000. Jackson Square Capital LLC acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth approximately $1,441,000. Finally, Harbor Capital Advisors Inc. boosted its position in Ascendis Pharma A/S by 67.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 87,302 shares of the biotechnology company’s stock valued at $13,035,000 after buying an additional 35,102 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.